BRANFORD, CT – (July 17, 2018) – Thetis Pharmaceuticals LLC, a privately-held biopharmaceutical company focused on gastrointestinal diseases, announced today that the USPTO has granted patent US 9,999,626 providing composition of matter protection for its IBD development candidates. The allowed claims include pharmaceutical compositions that are mineral amino-acid based derivatives of fatty acids with 16 to 24 carbons. National filings outside of the United States are underway.
Frank Sciavolino, Ph.D., co-founder, president and chief scientific officer of Thetis said, “This patent expands the intellectual property foundation of our strategy to develop innovative new therapies that deliver endogenous bioactive lipids through application of our proprietary HEALER technology platform. The industry has been seeking to harness this biology for decades. Our HEALER technology unlocks this biology by enabling new molecules with improved stability and composition of matter patent protection”.
Thetis Pharmaceuticals is a biopharmaceutical company developing novel therapies for the treatment of IBD and other inflammatory diseases. Thetis’ proprietary technology platform enables the pharmaceutical development of bioactive lipids that actively regulate inflammation and promote tissue repair and healing. Thetis’s technology overcomes the stability, manufacturing, formulation and patentability hurdles that have limited the development of bioactive lipids as pharmaceutical agents, unlocking their robust pharmacology to be developed as first-in-class therapeutics.